| 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 49,4 M € | -26.9% | 67,6 M € | -25.1% | 90,2 M € | -8.3% | 98,4 M € | +24.6% | 79,0 M € | +16.1% | 68,0 M € | +38.4% | 49,2 M € | +10.0% | 44,7 M € | -13.6% | 51,7 M € | +9.4% | 47,3 M € | +23.4% | 38,3 M € | +17.9% | 32,5 M € | +9.9% | 29,6 M € | -5.4% | 31,3 M € | -7.7% | 33,9 M € | +11.3% | 30,4 M € | -9.5% | 33,7 M € | +6.3% | 31,7 M € | +4.7% | 30,2 M € | |
| EBITDA | -8,4 M € | -28.2% | -6,5 M € | -173.2% | 8,9 M € | -65.0% | 25,4 M € | +19.6% | 21,3 M € | +61.8% | 13,1 M € | +465.1% | -3,6 M € | -134.4% | 10,5 M € | -6.8% | 11,2 M € | +14.0% | 9,8 M € | +63.5% | 6,0 M € | +38.7% | 4,3 M € | +101.2% | 2,2 M € | -18.9% | 2,7 M € | +5.9% | 2,5 M € | +204.4% | 825,2 k € | -86.0% | 5,9 M € | -3.3% | 6,1 M € | -1.1% | 6,2 M € | |
| Operating profit | -18,6 M € | -3.4% | -18,0 M € | -507.4% | -3,0 M € | -117.5% | 16,9 M € | +41.2% | 12,0 M € | +59.3% | 7,5 M € | +203.6% | -7,3 M € | -199.7% | 7,3 M € | -14.1% | 8,5 M € | +16.9% | 7,2 M € | +91.7% | 3,8 M € | +67.1% | 2,3 M € | +1808.9% | 118,3 k € | -76.3% | 499,3 k € | +145.3% | 203,6 k € | +111.4% | -1,8 M € | -156.1% | 3,2 M € | +12.8% | 2,8 M € | +41.4% | 2,0 M € | |
| Profit/loss | -20,4 M € | +43.8% | -36,3 M € | -611.1% | -5,1 M € | -137.0% | 13,8 M € | +23.7% | 11,2 M € | +49.5% | 7,5 M € | +214.3% | -6,5 M € | -217.3% | 5,6 M € | -14.9% | 6,5 M € | +67.9% | 3,9 M € | +30.7% | 3,0 M € | +30.6% | 2,3 M € | +794.8% | -328,7 k € | +73.3% | -1,2 M € | -151.1% | -490,8 k € | +67.2% | -1,5 M € | -145.9% | 3,3 M € | +68.1% | 1,9 M € | -6.7% | 2,1 M € | |
| Equity | -4,3 k € | -100.0% | 20,8 M € | -63.9% | 57,5 M € | -15.3% | 67,9 M € | +10.3% | 61,5 M € | +10.8% | 55,5 M € | +7.0% | 51,9 M € | -13.2% | 59,8 M € | +5.4% | 56,7 M € | +88.4% | 30,1 M € | +31.9% | 22,8 M € | +21.1% | 18,8 M € | +13.5% | 16,6 M € | -2.1% | 17,0 M € | -8.1% | 18,4 M € | -2.3% | 18,9 M € | -8.0% | 20,5 M € | +16.2% | 17,6 M € | +8.1% | 16,3 M € | |
| Total assets | 115,4 M € | -8.5% | 126,1 M € | -18.9% | 155,5 M € | +2.1% | 152,3 M € | +1.5% | 150,0 M € | +11.6% | 134,5 M € | +14.7% | 117,2 M € | -2.7% | 120,4 M € | +17.1% | 102,9 M € | +36.9% | 75,1 M € | +23.8% | 60,7 M € | +15.7% | 52,5 M € | -0.9% | 52,9 M € | +10.6% | 47,8 M € | -1.7% | 48,7 M € | +2.8% | 47,4 M € | +9.0% | 43,4 M € | +19.8% | 36,2 M € | +2.5% | 35,4 M € | |
| Cash | 628,6 k € | -23.0% | 816,5 k € | +11.5% | 732,2 k € | -16.4% | 876,4 k € | +64.8% | 531,9 k € | -53.1% | 1,1 M € | +26.4% | 897,6 k € | +256.0% | 252,2 k € | -55.0% | 560,8 k € | +448.1% | 102,3 k € | -69.4% | 334,7 k € | +333.2% | 77,3 k € | -57.0% | 179,6 k € | -73.9% | 687,1 k € | -68.8% | 2,2 M € | +510.5% | 360,4 k € | -47.7% | 689,3 k € | +550.8% | 105,9 k € | -61.7% | 276,8 k € | |
| Debts | 110,6 M € | +9.8% | 100,7 M € | +9.1% | 92,3 M € | +16.4% | 79,3 M € | -5.0% | 83,5 M € | +12.2% | 74,4 M € | +22.4% | 60,8 M € | +7.4% | 56,6 M € | +43.0% | 39,6 M € | -1.9% | 40,3 M € | +11.7% | 36,1 M € | +15.6% | 31,2 M € | -9.8% | 34,6 M € | +17.0% | 29,6 M € | +2.6% | 28,8 M € | +7.0% | 27,0 M € | +27.8% | 21,1 M € | +23.0% | 17,1 M € | -2.4% | 17,6 M € | |
| Staff | 379,2 | 405,2 | 418,9 | 394,7 | 360,1 | 340,8 | 316 | 284,6 | 260,2 | 239,7 | 222 | 208,5 | 219,9 | 229,3 | 225 | 232 | 241,5 | 236,5 | 228,3 | |||||||||||||||||||
Public limited company · Seraing · incorporated on 18/05/1985 · 379,2 ETP
Public limited company loss-making in the latest fiscal year. Cash position declining (-23.0%).
Solid counterparty for a standard engagement.
KANEKA EUROGENTEC is a Public limited company incorporated in 1985. Its main activity is: Manufacture of pharmaceutical preparations. Its registered office is in Seraing. It employs on average 379,2 ETP workers (FTE).
Key indicators
7-day free trial, no credit card required.
7-day free trial, no credit card required.
7-day free trial, no credit card required.
Source: Belgian Official Gazette